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In the last few years, hypofractionated external beam radiotherapy has gained increasing popularity for prostate
cancer treatment, since sufficient evidence exists that prostate cancer has a low α/β ratio, lower than the one of
the surrounding organs at risk and thus there is a potential therapeutic benefit of using larger fractionated single
doses. Apart from the therapeutic rationale there are advantages such as saving treatment time and medical resources
and thereby improving patient’s convenience. While older trials showed unsatisfactory results in both standard and
hypofractionated arm due to insufficient radiation doses and non-standard contouring of target volumes,
contemporary randomized studies have reported on encouraging results of tumor control mostly without an increase
of relevant side effects, especially late toxicity. Aim of this review is to give a detailed analysis of relevant, recently
published clinical trials with special focus on rationale for hypofractionation and different therapy settings.Rationale for hypofractionation in prostate cancer
treatment
The Linear Quadratic Model with its alpha/beta value de-
scribes the curvature of cell killing both for tumor control
and normal tissue complications in relationship to radio-
therapy dose. The alpha/beta ratio is the dose where the
linear as well as the quadratic component cause the same
amount of cell killing. Generally speaking, the higher the
alpha/beta ratio is, the more linear the cell survival curve
is. Whereas the lower the alpha/beta ratio is (high beta
relative to alpha), the more curved the cell survival curve
is. This is important, as tissues with a low alpha/beta are
relatively resistant to low doses in contrast to tissues with
a high alpha/beta. Thus early responding tissues or rapidly
proliferating tumors have a high alpha/beta ratio of
more than 10 Gy and late responding tissues or slowly
proliferating tumors have a low alpha beta ratio of around
3–5 Gy. Most tumors have a high alpha/beta ratio and
can therefore be reasonably treated with conventionally
fractionated radiotherapy (using single doses of 1.8 –
2.0 Gy). But some tumors, i.e. melanoma, sarcoma and
prostate cancer have a very low alpha/beta ratio and
therefore higher single doses can be applied with the
aim of achieving better tumor control with approximately
the same side effects [1,2]. Furthermore the rationale of* Correspondence: minglun.li@med.uni-muenchen.de
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unless otherwise stated.fractionation in radiotherapy is also based upon the higher
repair-capacity of normal tissue compared to tumor cells,
allowing an immediate repair of most radiation-induced
sub-lethal lesions in normal tissues between the fractions
and thus allowing a relative tumor-specific therapeutic ef-
fect [3]. A further reason for hypofractionated prostate
cancer treatment is that the surrounding late-responding
organs at risk, i.e. rectum or bladder have an estimated
α/β-level of 3–5 Gy. Hypothesizing on an α/β-level of
1.5 Gy for prostate cancer and of 3 Gy for rectum, it can
be concluded that prostate cancer cells are more re-
sponsive to a larger fraction size and that due to a lower
α/β-level of prostate cancer cells in comparison with the
surrounding late responding tissues there is even a thera-
peutic gain by using larger fractions sizes [4]. Historically
already 15 years ago, there have been attempts to estimate
α/β-values for prostate cancer by taking into account re-
sults from external beam radiotherapy and brachytherapy.
On account of these findings one came up with an α/β-
value as low as 1.5 Gy for prostate cancer [5,6]. Fowler
et al. have also studied the clinical outcome of patients
treated with EBRT or with brachytherapy using I-125 or
Pd-103 implants and have also calculated an α/β-value of
lower than 2 Gy for prostate cancer [7]. However this
must be viewed with caution, since the biological anti-
tumor-activity and the dose distributions of high and low
dose brachytherapy are not the same as that of EBRT and
data sets from different institutions were compared [8].
For example it is still not known, whether there aretral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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of disease.
To further clarify these issues, Miralbell et al. [2] have
recently published data of nearly 6000 patients with dif-
ferent prostate cancer risk groups, all treated with exter-
nal beam radiotherapy either with standard fractionation
(1.8 - 2.0 Gy per fraction; 40% of the patients) or hypo-
fractionation (2.5 - 6.7 Gy per fraction; 60% of the pa-
tients). At 5 years tumor control was calculated by using
the Phoenix criteria of biochemical relapse free survival,
that represents local as well as distant failure and an α/β-
value of 1.4 Gy (95% CI = 0.9-2.2) was obtained using the
linear-quadratic model [2]. This is so far the most precise
estimation of α/β-ratio for EBRT with the largest patient
collection. Interestingly, androgen deprivation did not
affect the α/β-value, though there was an improvement of
bNED for all three risk groups by 5%. Moreover there was
not a significant difference in the α/β-values of the three
prostate cancer risk-groups [2]. In a further recent analysis
of 274 patients with localized prostate cancer hypofractio-
nated radiotherapy of 20 fractions using 3.0 or 3.15 Gy
was compared to conventionally fractionated radiotherapy
with a median treatment time of 55 days (range 49–66).
The calculated α/β-ratio for prostate cancer was 1.86 Gy,
with a huge 95%-confidence-interval of 0.7 - 5.1 Gy due
to the relatively small number of treated patients [9]. In
order to safely apply high single doses, it is vital to know,
whether the surrounding organs at risk have a low α/β-
ratio as well. A prospective phase II study was conducted
by Marzi et al. to estimate the α/β-ratio of the rectum as
the main dose-limiting organ at-risk: Patients were either
treated with a conventional (80 Gy in 40 fractions over
8 weeks) or a hypofractionated (62 Gy in 20 fractions over
5 weeks) schema. An α/β-ratio of very close to 3 Gy was
found for late rectal toxicity and there was no difference
of late rectal toxicity between conventional or hypofractio-
nated radiation [10].
Hypofractionated radiotherapy as primary therapy for
prostate cancer
The first studies about hypofractionation were published
in the 1990s in the UK, Australia and Canada, where due
to long driving distances to the next radiation-oncology
department and due to for these countries’ characteristic
health care reimbursements the interest in hypofractiona-
tion is evident: Lukka et al. conducted in Canada a phase
III study comparing conventionally fractionated radiother-
apy (66 Gy in 33 fractions) with hypofractionated (52,5 Gy
in 20 fractions). Primary outcome was biochemical or
clinical failure (BCF), whereas secondary outcomes in-
cluded presence of tumor at 2 years, survival and tox-
icity. At 5 year’s follow-up primary outcome (52,95% vs.
59,95%), as well as acute toxicity were both worse in the
hypofractionated in comparison to the conventionallyfractionated arm, although without a difference in late
toxicity, in 2-year post-radiotherapy biopsy or overall sur-
vival [11]. In Australia Yeoh et al. conducted a study from
1996 until 2003 comparing toxicity and efficacy of radi-
ation therapy for localized carcinoma of the prostate using
a hypofractionated (55 Gy/20 fractions/4 weeks) vs. a con-
ventionally fractionated (64 Gy/32 fractions/6.5 weeks)
dose schedule. At a follow-up for a median of 90 months
biochemical relapse free survival according the Phoenix
criteria was significantly better in the hypofractionated
group than in the conventionally fractionated group, but
not overall survival. Gastrointestinal and genitourinary
toxicity did not differ between the two dose schedules.
According to Yeoh et al. there is a great therapeutic ad-
vantage of hypofractionated compared to conventionally
fractionated dose schedule for radiotherapy of prostate
cancer [12,13]. Both studies need to be critically commen-
ted on: First in both studies overall doses were underdosed
compared to nowadays conventionally fractionated overall
doses of 74.0-80.0 Gy. Second planning was undertaken
mostly by 2D-plans, and not at least by nowadays stand-
ardly used 3D-plans or even IMRT plans. Therefore these
two studies resulted in a much higher toxicity rate than
one would expect nowadays. Third these trials did not
consider the α/β-ratio of prostate cancer before starting
and comparing hypofractionation to a conventionally frac-
tionated schedule. Therefore these two studies can be seen
as a first experiment with hypofractionation and have
shown, that it is feasible, but they lack in reasonable re-
sults due to older planning methods and underdose. Mod-
ern studies are based on an α/β-ratio of prostate cancer of
1.5 Gy and were conducted to either show the equivalent
effectiveness between the two fractionation schedules with
reduced side effects in the hypofractionated arm or to
show a higher effectiveness with equal toxicity due to a
higher biological effective dose.
The results of several such prospective trials with ad-
equate dose have been published now (Table 1). Arcangeli
et al. conducted a study in high-risk prostate cancer pa-
tients comparing conventional fractionation (80 Gy/2 Gy/
8 weeks) to hypofractionation (62 Gy/3.1 Gy/5 weeks). At
a follow-up of a median of 70 months there was a signifi-
cant risk reduction in biochemical failure (10.3 %), but not
in local or distant failure, when considering the entire
group of patients. Whereas there was a significant increase
of 5-year freedom from biochemical, local and even dis-
tant failure for a subgroup of patients with a pretreat-
ment PSA level of 20 ng/ml or less. This might be due
to a greater local effectiveness of hypofractionation on
a smaller tumor burden and thus due to the achieve-
ment of local tumor control before the occurrence of
metastatic spread. Arcangeli et al. have therefore shown
that hypofractionation in high risk prostate cancer is at
least isoeffective in regard of biochemical control [14].
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http://www.ro-journal.com/content/9/1/275Dearnaley et al. presented a preliminary safety analysis on
side effects of their CHHiP trial (Conventional or Hypo-
fractionated High-dose Intensity Modulated Radiotherapy
in Prostate Cancer). Patients were either treated with con-
ventionally fractionated (74 Gy/2 Gy) or hypofractionated
(60 Gy/3 Gy or 57 Gy/3 Gy) intensity modulated radio-
therapy and all patients received 3–6 months of neoadju-
vant androgen suppression. The primary endpoint was the
proportion of patients with grade 2 or worse toxicity at
2 years on the RTOG scale. Between the three groups
there was no significant difference in regard of bowel tox-
icity ≥ grade 2 or bladder toxicity ≥ grade 2 at a median
follow-up of 50.5 months and the overall number of inci-
dents was low. The effectiveness of these three radiother-
apy schemes has not yet been published [15]. Another two
fairly recently published studies have been performed with
modern radiation tools like IMRT [16,17]. Pollack et al.
treated 303 patients with favorable- to high-risk pros-
tate cancer with either conventionally fractionated IMRT
(CIMRT) with 76 Gy in 38 fractions at 2.0 Gy per fraction
or with hypofractionated IMRT (HIMRT) with 70.2 Gy in
26 fractions at 2.7 Gy per fraction (equivalent to 84.4 Gy
in 2.0 Gy fractions). With a median follow up 68.4 months
there was no significant difference in regard of bio-
chemical and/or clinical disease failure (BCDF) (21.4% for
CIMRT vs. 23.3% for HIMRT) nor in regard of late tox-
icity, although patients with compromised urinary func-
tion before enrollment had significantly worse urinary
function after HIMRT. Although this study did not result
in a significant reduction of BCDF, patients had the advan-
tage of 2.5 fewer treatment weeks and it was shown, that
hypofractionated IMRT could safely be applied apart from
patients with compromised urinary function.
Besides the prospective studies mentioned above,
Kupelian et al. reported on their experience of 770 pros-
tate cancer patients treated with hypofractionated radio-
therapy (70.0 Gy/2.5 Gy) in a retrospective analysis. Both
tumor control and toxicity rate were acceptable and com-
parable with data of conventionally fractionated radiother-
apy studies [18].
Several phase III non-inferiority trials are going on,
such as the RTOG 0415 and PROFIT trials. The RTOG
0415 trial compares a 70.0 Gy at 2.5 Gy-schedule with a
73.8 Gy at 1.8 Gy-schedule. This trial is primarily testing
non-inferiority, and secondarily toxicity. If the α/β-ratio
of prostate cancer is around 10, this trial will be able to
demonstrate at least iso-effectiveness between the two
fractionation schemes. However if the α/β-ratio is closer
to 1.5 Gy, as it is widely assumed to be, the hypofractio-
nated schema should result in a higher tumor control.
This trial is closed to accrual, but is not yet published.
So far it can be stated that hypofractionated schemes are
at least as effective and tolerable as conventionally frac-
tionated schemes. Whether hypofractionation causes lessside effects at a higher tumor control still needs to be
awaited and to be investigated in further trials.
Adjuvant or salvage hypofractionated radiotherapy
The significance of adjuvant radiotherapy has been clearly
proven in three phase III randomized trials [19-22]. Adju-
vant radiotherapy with a dose range from 60–64 Gy after
radical prostatectomy should be deployed in patients with
unfavorable risk factors such as pT3-prostate cancer and/
or positive surgical margins, especially in presence of high
Gleason scores [19-22]. If a biochemical failure occurs, a
salvage radiotherapy should be done. As most trials on
adjuvant or salvage radiotherapy were conducted with a
conventionally fractionated scheme, evidence on hypofrac-
tionation for these indications is scarce and only few trials
on this topic exist.
There are two Italian studies on adjuvant radiotherapy
with a hypofractionated scheme [23,24]; Table 2). Ippolito
et al. performed an IMRT based dose-finding trial with
four increasing simultaneous integrated boosts (56.8 Gy/
2.27 Gy; 59.7 Gy/2.39 Gy; 61.25 Gy/2.45 Gy and 62.5 Gy/
2.5 Gy) to the prostate bed while irradiating the pelvic
lymph nodes (45 Gy/1.8 Gy). No dose-limiting toxicity
was seen at a median follow-up time of 19 months and
therefore the recommended dose was 62.5 Gy in 2.5 Gy/
fraction [24]. In 2008 Cozzarini et al. also reported on
hypofractionated adjuvant radiotherapy of 50 patients,
using helical tomotherapy. They applied 58 Gy in 20 frac-
tions and assessed toxicity in comparison to their insti-
tutional 3D-CRT with a conventionally fractionated
dose scheme. Initially, they observed no difference in
acute grade 2–3 genitourinary and acute grade 2 gastro-
intestinal toxicity [23]. However, in the update report
now, they presented an unexpected high rate of severe late
urinary toxicity (16.5% patients at grade 3–4) in 247 pa-
tients after a median follow-up of 68 months [25]. More
importantly, the fraction size has been shown to be an in-
dependent prognostic factor for severe late urinary toxicity
in the univariable and multivariable Cox analysis. Thus
the authors appealed special caution of using hypofractio-
nated schedule in a postprostatectomy setting due to the
risk of severe late urinary toxicity.
In the setting of a biochemical failure, Kruser et al. pub-
lished their experience of hypofractionated radiotherapy
(65.0 Gy/2.5 Gy in 26 fractions) on 108 patients with a
median PSA elevation of 0.44 ng/ml after prostatectomy.
The therapeutic results were encouraging: There was a
67% ± 5.3% freedom from biochemical failure at 4 years
and there was only moderate toxicity with only one acute
grade 3 genitourinary and with no acute grade 3 gastro-
intestinal toxicity and no late grade 3 toxicities [26]. Hypo-
fractionated salvage radiotherapy in this study thus
resulted in a low rate of acute and late toxicity with good
tumor control while reducing overall treatment time.
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http://www.ro-journal.com/content/9/1/275As there is apart from these three studies only scarce
information on this topic, Krause et al. have initiated the
PRIAMOS trial to investigate safety and feasibility of
hypofractionated treatment of the prostate bed alone as
well as of the pelvic lymph nodes [27]. A total of 80
prostate cancer patients shall be enrolled, of whom 40
patients with a low risk of lymph node involvement will
receive 54 Gy/3 Gy in 18 fractions to prostate bed only,
whereas 40 patients with a high risk for lymph node in-
volvement will receive 45 Gy/2.5 Gy in 18 fractions to
the lymph nodes additionally. Assuming an α/β-ratio of
1.5 Gy for prostate cancer the biological effective dose
(BED) would be 69.4 Gy for the prostate bed and
51.4 Gy for the pelvic lymph nodes and therefore all well
below the tolerance doses of the respective surrounding
organs at risk, such as small bowel (BED 47.5 Gy; α/β-
ratio 7 Gy) and rectum (BED 63 Gy, α/β-ratio 4 Gy). Pa-
tient accrual started in March 2012 and end of accrual is
planned for March 2014. Therefore safety and tumor
control of prostate bed and lymph nodes both treated
with a hypofractionated schema still needs to be awaited.
All in all there is a hint so far for a potential advantage
of hypofractionated radiotherapy in adjuvant and salvage
treatment for prostate cancer, especially in the context
of resource-saving and patients’ convenience. However,
on the other side, the hypofractionation-associated late
toxicity may be also significantly increased so that now
in the absence of solid evidence careful attention should
be taken proposing hypofractionated radiotherapy in the
adjuvant or salvage setting outside well designed pro-
spective clinical trials.
Hypofractionated radiotherapy with pelvic lymph node
irradiation
Initially, hypofractionated radiotherapy was performed
to solely irradiate the prostate. With the wider spread of
3D-conformal radiation therapy technique, as well as of
IMRT, a more sophisticated dose delivery to the pros-
tate/prostate bed with a simultaneous radiation of pelvic
lymph nodes has been integrated in recent trials for pa-
tients with high risk for lymph node metastases. Since
radiotherapy-induced toxicities do not only depend on
the radiation dose but also on the irradiated volume of
organs at-risk [28], the addition of pelvic lymph nodes’
irradiation might increase the dose exposure, i.e. of rec-
tum or bladder, and thus the side effects.
Until now, several prospective and retrospective trials
have been published [24,29-34] on hypofractionated treat-
ment of the prostate/prostate bed with simultaneous con-
ventionally fractionated irradiation of the pelvic lymph
nodes (Table 3). So far apart from the above mentioned
and currently accruing trial on hypofractionated irradi-
ation of pelvic lymph nodes, no study has been published
so far on hypofractionation in pelvic lymph nodes’treatment. McDonald et al. [31] retrospectively collected
data on toxicity of patients, that either received an IMRT
based prostate-only radiotherapy (PORT, 70.0 Gy/2.5 Gy)
or an additional, conventionally fractionated whole-pelvic
radiotherapy (WPRT, 50.4 Gy/1.8 Gy). They hypothesized
that the treatment of pelvic lymph nodes will result in an
increased toxicity compared to hypofractionated treat-
ment of prostate only. They therefore retrospectively per-
formed a daily dosimetry for patients, who developed
grade 2 or higher late toxicities in order to correlate the
dose-levels to the rectum with the occurred toxicity. Con-
cerning acute gastrointestinal (GI) and genitourinary (GU)
toxicity there was no statistically significant difference
with the addition of elective node irradiation (ENI).
Whereas in regard to late grade ≥2 rectal toxicity there
was a statistically significant difference between WPRT-
group (18%) and PORT-group (0%) at a median follow-up
of 41.1 months. When retrospectively contouring the daily
CT-scans of patients, who developed a grade ≥ 2 rectal
toxicity, the combined average daily deviation of the actual
rectal volume from the planned volume was 12.7% and
88% of all fractions delivered a higher V70 than originally
planned. This study therefore showed that the addition of
ENI leads to a significant higher rate of late grade ≥2 rec-
tal toxicity and confirms the above mentioned hypothesis
that the dose exposure of the rectum increases with the ir-
radiation of larger volumes, like the inclusion of pelvic
lymph nodes. This finding is consistent with results of
studies with conventionally irradiated prostate and pelvic
lymph nodes, like GETUG-01 study [35] or with results
of hypofractionated irradiation of prostate with conven-
tional irradiated pelvic lymph nodes, like the study of
McCammon et al. [30], in which the actuarial rate of late
grade ≥2 GI events was 13.4% at 6 years. Furthermore
there is the study of Adkison et al. on dose-escalated treat-
ment of the pelvic lymph nodes with 56 Gy in conventional
fractionation combined with hypofractionated treatment
of the prostate (70 Gy in 2.5 Gy fractions), that was shown
to be well tolerated [29]. Recently Guckenberger et al. pre-
sented outcome and toxicity of 150 prostate cancer pa-
tients that either received an IMRT with mean total doses
of 73.9 Gy in 32 fractions or with mean total doses of
76.2 Gy in 33 fractions [34]. The pelvic lymph nodes were
treated in 41 high-risk patients with an overall dose of
45.0 Gy and a single fraction dose of 1.8 Gy. At a median
follow-up of 50 months only two patients suffered from
late grade 3 GI toxicity and > 80% of patients were free
from any GI toxicity during follow-up. Acute GU toxicity
grade 1–2 was observed in 85% of the patients with
most patients recovering from it within 6 weeks after
treatment. Interestingly the proportion of patients with
GU toxicity grade ≥2 was <10% at 6–12 months after
radiotherapy but increased continuously to 22.4% at
60 months. On univariate analysis it was shown that no
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risk of acute GU toxicity ≥2 and that treatment of the
whole pelvis had no effect on the rates of late GU toxicity
grade ≥2. With a 5-year freedom from biochemical failure
rate (FFBF) of 82% for all patients and an especially favor-
able rate of 78% for high-risk patients Guckenberger et al.
showed that a moderately hypofractionated IMRT also
with a simultaneous irradiation of pelvic lymph nodes
can be safely performed. So far hypofractionated treat-
ment of prostate in combination with conventionally
fractionated irradiation of pelvic lymph nodes seems to
be feasible at an acceptable toxicity rate, but data of the
study of Krause et al. [27] on hypofractionated treat-
ment of prostate as well as of pelvic lymph nodes are
most eagerly awaited.
Role of IMRT/IGRT in hypofractionation
The use of improved technology has fostered the in-
creasing interest in hypofractionated radiotherapy for
prostate cancer. Multiple studies have confirmed the im-
portance of delivering sufficiently high doses to prostate
in order to cure patients. Due to inverse planning, the
key factor of intensity modulated radiotherapy (IMRT)
dose distributions with a maximum sparing of organs at
risk are possible. Furthermore with the advances in im-
aging and onboard verification systems as part of image
guided radiotherapy (IGRT) the capabilities of IMRT en-
able an even more sophisticated dose distribution and
are the reasons for further dose escalation and hypofrac-
tionated schemes [36]. IMRT and IGRT are the tools that
allow the radiooncologist to safely deliver escalated sin-
gle and/or overall doses and are the primary intellectual
prerequisite to allow these therapeutic advances. While, as
stated above, hypofractionated radiotherapy may probably
result a higher biological equivalent dose to prostate can-
cer than to the surrounding normal tissues due to the
lower alpha/beta value of prostate cancer and thus protect
organs at risk in the biological perspective, IMRT and
IGRT with the geometric advantages of dose delivery may
potentially further increase the therapeutic ratio of hypo-
fractionated radiotherapy. Here we listed the relevant
hypofractionated trials using IMRT and IGRT in Table 4.
One of the most important findings on this topic are
the already above mentioned preliminary safety results
of the trial CHHiP (Conventional or Hypofractionated
High-dose Intensity Modulated Radiotherapy in Prostate
Cancer), where patients were either treated with conven-
tional (74 Gy/2 Gy) or hypofractionated (60 Gy/3 Gy or
57 Gy/3 Gy) intensity modulated radiotherapy (IMRT)
and all were given 3–6 months of neoadjuvant androgen
suppression. Between the three groups there was no sig-
nificant difference in regard of bowel toxicity or bladder
toxicity ≥ grade 2 at a median follow-up of 50.5 months
and the results from this pre-planned safety analysis ofthe first 457 patients, that were enrolled in the CHHiP
trial, suggest that high dose hypofractionated schedules
using single doses of 3 Gy in combination with intensity-
modulated radiotherapy are safe [15]. Besides deploying
IMRT, delineation of clinical target volumes and defining
its safety margins are vital for hypofractionation. Pollack
et al. first reported in 2006 on dosimetry and acute tox-
icity of their randomized hypofractionation dose escal-
ation trial, in which they compared a conventionally
fractionated Arm I (76 Gy in 38 fractions) with a hypo-
fractionated Arm II (70.2 Gy in 26 fractions). They applied
different planning target volume (PTV) margins in Arm I
and II. Margins of PTV were posteriorly 5 mm in Arm I
vs. 3 mm in Arm II and in all other dimensions 8 mm in
Arm I vs. 7 mm in Arm II. PTV D95% was at least the
prescription dose. Therefore the mean PTV doses for
Arms I and II were 81.1 Gy and 73.8 Gy. Due to these
planning conditions there were no differences in overall
acute gastrointestinal (GI) or genitourinary (GU) toxicity,
although there was a slight, but significant increase in
Arm II GI toxicity during weeks 2, 3 and 4 [37]. In 2013
Pollack et al. presented an update of this study (303 as-
sessable patients) with emphasis on late toxicity and bio-
chemical and/or clinical disease failure (BCDF). At a
median follow-up of 68.4 months there were statistically
no significant differences in late toxicity between the two
arms, however in subgroup analysis, patients with com-
promised urinary function before enrollment had signifi-
cantly worse urinary function after hypofractionated
radiotherapy and therefore might not be ideal candidates
for a hypofractionated approach. In regard of 5-year rates
of BCDF the study of Pollack et al. did not show a signifi-
cant difference (21.4% in conventionally fractionated
group versus 23.3% in hypofractionated group) with no
difference in the use of androgen deprivation therapy in
the two groups [16]. Reducing safety margins of PTV and
thereby reducing a possible overlap with the surrounding
organs at risk, particularly the rectum is only possible by
using image guided radiotherapy (IGRT). Only the use of
IGRT allows the control of inter- and intrafraction mo-
tions of target volumes and therefore allows a more pre-
cise dose delivery with smaller safety margins. This has
not only been proven in conventionally fractionated stud-
ies with dose escalation, like the study of Pinkawa et al.
[38], but also for hypofractionated regimes. Kupelian
et al. first published in 2000 about their “Cleveland ex-
perience” on short-course intensity-modulated radio-
therapy (70.0 Gy in 28 fractions) in the treatment of
localized prostate cancer while using daily transabdom-
inal ultrasound for localization [39]. They reported on
their first 51 patients that were treated with an intensity
modulated radiotherapy plan with safety margins for
the planning target volume (PTV) of 4 mm posteriorly,
8 mm laterally and 5 mm in all other directions. The
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http://www.ro-journal.com/content/9/1/275location of the prostate gland was verified daily with the
BAT transabdominal ultrasound system and patient pos-
ition adjustments were performed accordingly. These pa-
tients were compared in regard to acute bladder and
rectal toxicity with prostate cancer patients, that have
been treated with a more standard conformal technique
(78 Gy/2 Gy per fraction) and there was no statistical dif-
ference in the frequencies of acute bladder or acute rectal
toxicity [18]. Furthermore the insertion of fiducial markers
(gold seeds) in the prostate helps the radiooncologist to
daily monitor deviations regardless of whether they use
ultrasound or a CT based system for IGRT [40]. For sure
it is possible to do daily low dose CT controls, but espe-
cially for the prostate gland IGRT with ultrasound can
easily be used. All in all IMRT and IGRT are the require-
ments to safely apply hypofractionated schemes.
Stereotactic body radiotherapy and intense
hypofractionation
Stereotactic body radiotherapy (SBRT) with a fraction size
larger than 5 Gy has emerged as a further option to treat
prostate cancer with the potential advantage for the pa-
tient of an even shorter treatment time. However, on the
other side, it remains controversial how far the linear-
quadratic model is still valid using such a large dose size.
So far, most clinical trials on stereotactic body radiother-
apy were performed for organ-confined low risk prostate
cancer [41-46]. One of the pioneers in this field is C.R.
King. In 2012 he published results of their ongoing pro-
spective Phase II clinical trial using SBRT for low-risk
prostate cancer. From 2003 through 2009, 67 patients
with clinically localized low-risk prostate cancer received
36.25 Gy in 5 fractions with CyberKnife system as the de-
livery technology and without any further therapy, such as
hormonal ablation. At a median follow-up of 2.7 years late
RTOG Grade III, II and I bladder toxicities were seen in 2,
3 and 13 patients with no late urinary Grade IV toxicity.
Late rectal Grade III, II and I toxicities were seen in 0, 1
and 7 patients with no persistent rectal bleeding. The 4-
year Kaplan-Meier PSA relapse-free survival was 94% and
is similar to other definitive treatments [43]. Even though
these are excellent results, C.R. King and his co-publishers
advice to act with caution and to enroll patients for SBRT
primarily in clinical trials, as so far long term results for
therapeutic efficacy and toxicities are not completely
sufficient.
He further reported on a prospective Phase II clinical
trial that confirmed the advantage of every-other-day
treatment. In this trial forty-one low-risk prostate cancer
patients with 6 months’ minimum follow-up received as
well 36.25 Gy in five fractions of 7.25 Gy on 5 consecutive
days or every-other-day with image-guided SBRT using
as well the CyberKnife. In this study a reduced rate of
severe rectal toxicities was observed with every-other-dayvs. 5 consecutive days treatment regimen (0% vs. 38%,
p = 0.0035). Given their observations, they favor treating
with a longer interval between fractions for hypofrac-
tionated dose regimens [46].
King et al. have also analyzed health-related quality of
life (QOL) in patients treated with SBRT (median dose of
36.25 Gy in 4 or 5 fractions). 864 patients from a phase 2
clinical trial of SBRT for localized prostate cancer reported
QOL at baseline and at regular intervals up to 6 years. 194
patients remained evaluable at 5 years. It showed, that a
transient decline in urinary and bowel domains was ob-
served within the first 3 months after SBRT which
returned to baseline status or better within 6 months and
remained so beyond 5 years. The same pattern was ob-
served among patients with good versus poor baseline
function and was independent of the degree of early toxic-
ities. Thus this demonstrates that prostate SBRT is well
tolerated and has little lasting impact on health-related
QOL [47].
For intermediate-risk or high-risk prostate cancer, there
is even scarcer evidence, as only few trials on SBRT for
prostate cancer patients with these features exist. Katz
et al. are among those, who treated apart from low- (n =
211), also intermediate- (n = 81) and even high-risk pros-
tate cancer patients (n = 12) with SBRT [48]. 57 of these
patients received neoadjuvant hormonal therapy for up to
one year. The first 50 patients received a total dose of
35 Gy in 5 fractions with a single dose of 7 Gy that cov-
ered at least 96% of the PTV. The subsequent 254 patients
received a total dose of 36.25 Gy in 5 fractions with a sin-
gle dose of 7.25 Gy that covered as well at least 96% of the
PTV. The median follow-up of all patients was 60 months
(72 months for those with a lower and 60 months for
those with a higher overall dose). There was no acute
urinary or rectal toxicity Grade III or IV and fewer than
5% of patients experienced any Grade II urinary or rectal
toxicities. In regard to late toxicity there were 4% respect-
ively 2% of patients in the 35 Gy group, who experienced
urinary/rectal Grade II complications, whereas in the
36.25 Gy group there were 9% respectively 5% patients
with urinary/rectal Grade II toxicity and 2% with late
Grade III urinary toxicity. 5-year biochemical recurrence-
free survival was 97% for low-risk, 90.7% for intermediate-
risk and 74.1% for high risk patients. Although the results
for high-risk patients in this study are encouraging, one
must note that only 12 high-risk patients were included
and further data is needed.
In regard of dose escalation Kim et al. were among the
first to undertake a dose study of SBRT with 45, 47.5
and 50 Gy in 5 fractions for localized prostate cancer, in
which 91 patients were enrolled. At the highest dose
level, 6.6% of patients treated developed high-grade rec-
tal toxicity, 5 of whom required colostomy. Grade 3+ de-
layed rectal toxicity was strongly correlated with volume
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treatment of >35% circumference of rectal wall to 39 Gy
(p = 0.003). Grade 2+ acute rectal toxicity was significantly
correlated with treatment of >50% circumference of rectal
wall to 24 Gy (p = 0.010). The authors of this study there-
fore advise caution when considering high-dose SBRT for
treatment of tumors near bowel structures, including
prostate cancer and recommend to respect the above
mentioned threshold dose constraints in order to minimize
risk of severe rectal toxicity [49].
Provided that prostate motion is tracked and accounted
for (IGRT), high dose SBRT for prostate cancer may be-
come an attractive option especially for low- and
intermediate-risk patients. Regardless of whatsoever
risk group, patients who choose SBRT as primary treat-
ment should be enrolled in clinical trials, as the evidence
is still very limited.
Conclusion
There is a growing body of evidence suggesting that pros-
tate cancer has a low α/β-level of 1.4 Gy and therefore
lower than that of surrounding organs at risk, such as rec-
tum or bladder. This poses a therapeutic rationale for
hypofractionation with the possible result of a better
tumor control at a lower toxicity rate. Vital for a safe ap-
pliance of hypofractionated schemes are IMRT and IGRT.
These tools are the technical prerequisite for administer-
ing high single doses. So far there are encouraging results
for moderately as well as for higher hypofractionated
schemes regardless of the prostate cancer risk group.
Nevertheless there are still pending questions and ongoing
trials, as well as further follow-up of already conducted tri-
als that need to be awaited, before hypofractionated radio-
therapy can be generally recommended. Therefore so far
patients who are intended to be treated with a hypofrac-
tionated scheme should be enrolled in clinical trials. This
is also the case for patients that are to be treated with
stereotactic body radiotherapy, which might be even more
convenient to patients due to the use of higher single
doses and thus shorter treatment time.
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